Goal 2: Reduce Human Disease

Development of Optimally Hemostatic, Systemically Safe, Platelet Mimetics or Substitutes

What are the knowledge and technological gaps in production, evaluation and clinical translation of donor-independent platelets for transfusions? Specific questions include: a) How can stem or progenitor cells be expanded to maximize platelet production?; b) What are the hemostatically relevant design and function requirements and evaluation metrics for ideal/optimal “biologic” and “synthetic” platelets? c) What preclinical safety and quality assessments of donor-independent platelets will be required prior to clinical trials? And d) Are donor-independent platelets safe and effective for the prevention and treatment of thrombocytopenic patients?

Tags (Keywords associated with the idea)

Voting

20 net votes
38 up votes
18 down votes
Active
Idea No. 431